Loading
Small Cell Lung Cancer · Observational Study
ClinicalTrials.gov · August 5, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned prospective observational study registered to collect blood samples from an estimated 25 SCLC patients receiving tarlatamab at defined timepoints (days 1, 8, 15, and post-scan) to characterize drug exposure in real-world practice. No results have been posted to the registry; the study has not yet begun recruitment.
Observational. Small-cell Lung Cancer; age from 18 Years. Intervention: Prospective blood sample collection from patients on tarlatamab treatment at defined timepoints.. n = 25. Duke University (lead sponsor); no multicenter sites named..
This is a planned prospective observational study registered to collect blood samples from an estimated 25 SCLC patients receiving tarlatamab at defined timepoints (days 1, 8, 15, and post-scan) to characterize drug exposure in real-world practice. No results have been posted to the registry; the study has not yet begun recruitment.
No efficacy, safety, or clinical outcome measures are planned as primary endpoints.
Results from this study may inform understanding of tarlatamab pharmacokinetics and exposure variability in routine clinical practice, potentially supporting dosing optimization or monitoring strategies. However, clinicians should await publication of results before drawing conclusions.
This is an ongoing observational registry record with no results posted; it describes a planned blood collection study to characterize tarlatamab pharmacology in real-world SCLC treatment.
As stated by the source record.
Quoted from the source exactly as published.
Results from this study may inform understanding of tarlatamab pharmacokinetics and exposure variability in routine clinical practice, potentially supporting dosing optimization or monitoring strategies. However, clinicians should await publication of results before drawing conclusions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07468656). This is a study registration, not published results. Lead sponsor: Duke University. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 25 participants (ESTIMATED). Conditions: Small-cell Lung Cancer. Primary outcome measures: Number of blood samples collected to better characterize tarlatamab in real-world setting , Days 1, 8, and 15 of tarlatamab and after each interval scan for disease assessment. Brief summary: The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting. The investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.